

Postmenopausal Vaginal Atrophy (PVA) Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/P7AEE9AEE914EN.html>

Date: February 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: P7AEE9AEE914EN

Abstracts

This report contains market size and forecasts of Postmenopausal Vaginal Atrophy (PVA) Treatment in Global, including the following market information:

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Postmenopausal Vaginal Atrophy (PVA) Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Systemic Estrogen Treatments Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Postmenopausal Vaginal Atrophy (PVA) Treatment include EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD, Bionovo, Pfizer, Novo Nordisk, Allergan, Shionogi and Ligand Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Postmenopausal Vaginal Atrophy (PVA) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends,

drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, by Type, 2021 (%)

Systemic Estrogen Treatments

Non-estrogenic Therapies

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinics

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Postmenopausal Vaginal Atrophy (PVA) Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Postmenopausal Vaginal Atrophy (PVA) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

EndoCeutics

Upsher-Smith Laboratories

TherapeuticsMD

Bionovo

Pfizer

Novo Nordisk

Allergan

Shionogi

Ligand Pharmaceuticals

Bayer

Pantarhei Bioscience

Foamix Pharmaceuticals

Pep-Tonic Medical

Teva Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY (PVA) TREATMENT OVERALL MARKET SIZE

- 2.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size: 2021 VS 2028
- 2.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market
- 3.2 Top Global Postmenopausal Vaginal Atrophy (PVA) Treatment Companies Ranked by Revenue
- 3.3 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Postmenopausal Vaginal Atrophy (PVA) Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market

3.6.1 List of Global Tier 1 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Markets, 2021 & 2028

4.1.2 Systemic Estrogen Treatments

4.1.3 Non-estrogenic Therapies

4.2 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts

4.2.1 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2022

4.2.2 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2023-2028

4.2.3 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinics

5.2 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts

5.2.1 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2022

5.2.2 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2023-2028

5.2.3 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2021 & 2028

6.2 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts

6.2.1 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2022

6.2.2 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2023-2028

6.2.3 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028

6.3.2 US Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.3.3 Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.3.4 Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028

6.4.2 Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.3 France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.4 U.K. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.5 Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.6 Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.4.8 Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028

6.5.2 China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.5.3 Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size,

2017-2028

6.5.4 South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.5.6 India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028

6.6.2 Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.6.3 Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028

6.7.2 Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.7.3 Israel Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

6.7.5 UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 EndoCeutics

7.1.1 EndoCeutics Corporate Summary

7.1.2 EndoCeutics Business Overview

7.1.3 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.1.4 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.1.5 EndoCeutics Key News

7.2 Upsher-Smith Laboratories

7.2.1 Upsher-Smith Laboratories Corporate Summary

7.2.2 Upsher-Smith Laboratories Business Overview

7.2.3 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.2.4 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.2.5 Upsher-Smith Laboratories Key News

7.3 TherapeuticsMD

7.3.1 TherapeuticsMD Corporate Summary

7.3.2 TherapeuticsMD Business Overview

7.3.3 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.3.4 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.3.5 TherapeuticsMD Key News

7.4 Bionovo

7.4.1 Bionovo Corporate Summary

7.4.2 Bionovo Business Overview

7.4.3 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.4.4 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.4.5 Bionovo Key News

7.5 Pfizer

7.5.1 Pfizer Corporate Summary

7.5.2 Pfizer Business Overview

7.5.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.5.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.5.5 Pfizer Key News

7.6 Novo Nordisk

7.6.1 Novo Nordisk Corporate Summary

7.6.2 Novo Nordisk Business Overview

7.6.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.6.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.6.5 Novo Nordisk Key News

7.7 Allergan

7.7.1 Allergan Corporate Summary

7.7.2 Allergan Business Overview

7.7.3 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product

Offerings

7.7.4 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.7.5 Allergan Key News

7.8 Shionogi

7.8.1 Shionogi Corporate Summary

7.8.2 Shionogi Business Overview

7.8.3 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product

Offerings

7.8.4 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.8.5 Shionogi Key News

7.9 Ligand Pharmaceuticals

7.9.1 Ligand Pharmaceuticals Corporate Summary

7.9.2 Ligand Pharmaceuticals Business Overview

7.9.3 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment

Major Product Offerings

7.9.4 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.9.5 Ligand Pharmaceuticals Key News

7.10 Bayer

7.10.1 Bayer Corporate Summary

7.10.2 Bayer Business Overview

7.10.3 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product

Offerings

7.10.4 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.10.5 Bayer Key News

7.11 Pantarhei Bioscience

7.11.1 Pantarhei Bioscience Corporate Summary

7.11.2 Pantarhei Bioscience Business Overview

7.11.3 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Major

Product Offerings

7.11.4 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.11.5 Pantarhei Bioscience Key News

7.12 Foamix Pharmaceuticals

7.12.1 Foamix Pharmaceuticals Corporate Summary

7.12.2 Foamix Pharmaceuticals Business Overview

7.12.3 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.12.4 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.12.5 Foamix Pharmaceuticals Key News

7.13 Pep-Tonic Medical

7.13.1 Pep-Tonic Medical Corporate Summary

7.13.2 Pep-Tonic Medical Business Overview

7.13.3 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.13.4 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.13.5 Pep-Tonic Medical Key News

7.14 Teva Pharmaceuticals

7.14.1 Teva Pharmaceuticals Corporate Summary

7.14.2 Teva Pharmaceuticals Business Overview

7.14.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings

7.14.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2017-2022)

7.14.5 Teva Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Opportunities & Trends in Global Market

Table 2. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers in Global Market

Table 3. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints in Global Market

Table 4. Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment in Global Market

Table 5. Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Postmenopausal Vaginal Atrophy (PVA) Treatment Product Type

Table 9. List of Global Tier 1 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment
Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment
Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment
Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment
Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment
Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. EndoCeutics Corporate Summary

Table 31. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Product
Offerings

Table 32. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue
(US\$, Mn), (2017-2022)

Table 33. Upsher-Smith Laboratories Corporate Summary

Table 34. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA)
Treatment Product Offerings

Table 35. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA)
Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. TherapeuticsMD Corporate Summary

Table 37. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Product
Offerings

Table 38. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue
(US\$, Mn), (2017-2022)

Table 39. Bionovo Corporate Summary

Table 40. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 41. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Pfizer Corporate Summary

Table 43. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 44. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Novo Nordisk Corporate Summary

Table 46. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 47. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Allergan Corporate Summary

Table 49. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 50. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Shionogi Corporate Summary

Table 52. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 53. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Ligand Pharmaceuticals Corporate Summary

Table 55. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 56. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Bayer Corporate Summary

Table 58. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 59. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Pantarhei Bioscience Corporate Summary

Table 61. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 62. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. Foamix Pharmaceuticals Corporate Summary

Table 64. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 65. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. Pep-Tonic Medical Corporate Summary

Table 67. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 68. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

Table 69. Teva Pharmaceuticals Corporate Summary

Table 70. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings

Table 71. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Segment by Type in 2021
- Figure 2. Postmenopausal Vaginal Atrophy (PVA) Treatment Segment by Application in 2021
- Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in 2021
- Figure 8. By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028
- Figure 12. US Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$,

Mn), 2017-2028

Figure 20. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

Figure 24. China Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Postmenopausal Vaginal Atrophy (PVA) Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/P7AEE9AEE914EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7AEE9AEE914EN.html>